keyword
MENU ▼
Read by QxMD icon Read
search

meta antipsychotic

keyword
https://www.readbyqxmd.com/read/28727644/cariprazine-specificity-profile-in-the-treatment-of-acute-schizophrenia-a-meta-analysis-and-meta-regression-of-randomized-controlled-trials
#1
Filippo Corponi, Alessandro Serretti, Stuart Montgomery, Chiara Fabbri
Cariprazine is a new dopamine D2 and D3 receptor partial agonist antipsychotic. Meta-analytic evidence of efficacy in acute schizophrenia and specific groups of patients is lacking. We carried out a meta-analysis in patients with acute schizophrenia to evaluate the efficacy of cariprazine over placebo and active comparators in overall symptoms, positive and negative symptoms and quality of life. Low and high (≥6 mg/day) doses were tested separately. The possible effect of clinical-demographic modulators was also tested...
July 19, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28727483/pharmacological-treatment-of-tardive-dyskinesia-recent-developments
#2
Stanley N Caroff, E Cabrina Campbell, Benjamin Carroll
Tardive dyskinesia (TD) occurs in patients receiving antipsychotic treatment with dopamine receptor antagonists. Despite the prevalence of TD and its negative impact on patients' lives, there has been a lack of approved treatments and limited evidence from controlled trials of pharmacological treatment. Areas covered: PubMed was searched for English-language papers published during 2007-2016 using terms "tardive dyskinesia" or "drug-induced movement disorder", and "treatment". Studies evaluating pharmacological agents for the treatment of TD were selected...
July 20, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28721057/safety-tolerability-and-risks-associated-with-first-and-second-generation-antipsychotics-a-state-of-the-art-clinical-review
#3
REVIEW
Marco Solmi, Andrea Murru, Isabella Pacchiarotti, Juan Undurraga, Nicola Veronese, Michele Fornaro, Brendon Stubbs, Francesco Monaco, Eduard Vieta, Mary V Seeman, Christoph U Correll, André F Carvalho
Since the discovery of chlorpromazine (CPZ) in 1952, first-generation antipsychotics (FGAs) have revolutionized psychiatric care in terms of facilitating discharge from hospital and enabling large numbers of patients with severe mental illness (SMI) to be treated in the community. Second-generation antipsychotics (SGAs) ushered in a progressive shift from the paternalistic management of SMI symptoms to a patient-centered approach, which emphasized targets important to patients - psychosocial functioning, quality of life, and recovery...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/28718688/effect-of-adjunctive-ranitidine-for-antipsychotic-induced-weight-gain-a-systematic-review-of-randomized-placebo-controlled-trials
#4
Xiao-Jing Gu, Rui Chen, Chen-Hui Sun, Wei Zheng, Xin-Hu Yang, Shi-Bin Wang, Gabor S Ungvari, Chee H Ng, Andrei Golenkov, Grace K I Lok, Lu Li, Ines H I Chow, Fei Wang, Yu-Tao Xiang
This study was a meta-analysis of randomized controlled trials (RCTs) of ranitidine as an adjunct for antipsychotic-induced weight gain in patients with schizophrenia. RCTs reporting weight gain or metabolic side effects in patients with schizophrenia were included. Case reports/series, non-randomized or observational studies, reviews, and meta-analyses were excluded. The primary outcome measures were body mass index (BMI) (kg/m(2)) and body weight (kg). Four RCTs with five study arms were identified and analyzed...
January 1, 2017: Journal of International Medical Research
https://www.readbyqxmd.com/read/28712616/aripiprazole-lauroxil-compared-with-paliperidone-palmitate-in-patients-with-schizophrenia-an-indirect-treatment-comparison
#5
Chris Cameron, Jacqueline Zummo, Dharmik N Desai, Christine Drake, Brian Hutton, Ahmed Kotb, Peter J Weiden
BACKGROUND: Aripiprazole lauroxil (AL) is a long-acting injectable atypical antipsychotic recently approved for treatment of schizophrenia on the basis of a large-scale trial of two doses of AL versus placebo. There are no direct-comparison studies with paliperidone palmitate (PP; long-acting antipsychotic used most often in acute settings) for the acute psychotic episode. OBJECTIVES: To indirectly compare efficacy and safety of the pivotal AL study with all PP studies meeting indirect comparison criteria...
July 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28700715/the-pharmacological-and-non-pharmacological-treatment-of-attention-deficit-hyperactivity-disorder-in-children-and-adolescents-a-systematic-review-with-network-meta-analyses-of-randomised-trials
#6
Ferrán Catalá-López, Brian Hutton, Amparo Núñez-Beltrán, Matthew J Page, Manuel Ridao, Diego Macías Saint-Gerons, Miguel A Catalá, Rafael Tabarés-Seisdedos, David Moher
BACKGROUND: Attention deficit hyperactivity disorder (ADHD) is one of the most commonly diagnosed psychiatric disorders in childhood. A wide variety of treatments have been used for the management of ADHD. We aimed to compare the efficacy and safety of pharmacological, psychological and complementary and alternative medicine interventions for the treatment of ADHD in children and adolescents. METHODS AND FINDINGS: We performed a systematic review with network meta-analyses...
2017: PloS One
https://www.readbyqxmd.com/read/28697802/outcomes-of-subsyndromal-delirium-in-icu-a-systematic-review-and-meta-analysis
#7
Rodrigo B Serafim, Marcio Soares, Fernando A Bozza, José R Lapa E Silva, Felipe Dal-Pizzol, Maria Carolina Paulino, Pedro Povoa, Jorge I F Salluh
BACKGROUND: Subsyndromal delirium (SSD) is a frequent condition and has been commonly described as an intermediate stage between delirium and normal cognition. However, the true frequency of SSD and its impact on clinically relevant outcomes in the intensive care unit (ICU) remains unclear. METHODS: We performed a systematic search in PubMed, Embase, CINAHL, Cochrane Library, and PsychINFO, with no language restrictions, up to 1 October 2016 to identify publications that evaluated SSD in ICU patients...
July 12, 2017: Critical Care: the Official Journal of the Critical Care Forum
https://www.readbyqxmd.com/read/28696411/combined-study-of-genetic-and-epigenetic-biomarker-risperidone-treatment-efficacy-in-chinese-han-schizophrenia-patients
#8
Y Shi, M Li, C Song, Q Xu, R Huo, L Shen, Q Xing, D Cui, W Li, J Zhao, L He, S Qin
Nowadays, risperidone is an atypical antipsychotic drug that has been increasingly used for treatment and maintenance therapy in schizophrenia. However, partially affected by genetic or environmental factors, there is significant difference in treatment outcomes among patients. In this study, we aimed to interpret the difference between good and poor responders treated with risperidone in both genetic and epigenetic levels in 288 mainland Chinese patients. We recruited a Henan cohort including 98 patients as initial discovery group and then confirmed our results in Shanghai cohort...
July 11, 2017: Translational Psychiatry
https://www.readbyqxmd.com/read/28669774/how-well-do-patients-with-a-first-episode-of-schizophrenia-respond-to-antipsychotics-a-systematic-review-and-meta-analysis
#9
REVIEW
Yikang Zhu, Chunbo Li, Maximilian Huhn, Philipp Rothe, Marc Krause, Irene Bighelli, Johannes Schneider-Thoma, Stefan Leucht
It is often stated that first-episode patients tend to respond better to antipsychotics than chronic patients, but the exact numbers and moderators of response in this population are unclear. We, therefore, present the first systematic review on response rates of first episode patients with schizophrenia in randomized trials. We searched multiple databases for randomized-controlled trials of antipsychotics in acutely ill patients with a first episode of schizophrenia (last search: November 17, 2016). The outcomes were response rate based on two criteria, at least 50% PANSS or BPRS total score reduction from baseline and at least 20% reduction...
June 29, 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28658515/antipsychotic-combinations-for-schizophrenia
#10
REVIEW
Javier Ortiz-Orendain, Santiago Castiello-de Obeso, Luis Enrique Colunga-Lozano, Yue Hu, Nicola Maayan, Clive E Adams
BACKGROUND: Many people with schizophrenia do not achieve a satisfactory treatment response with their initial antipsychotic drug treatment. Sometimes a second antipsychotic, in combination with the first, is used in these situations. OBJECTIVES: To examine whether:1. treatment with antipsychotic combinations is effective for schizophrenia; and2. treatment with antipsychotic combinations is safe for the same illness. SEARCH METHODS: We searched the Cochrane Schizophrenia Group's register which is based on regular searches of CINAHL, BIOSIS, AMED, Embase, PubMed, MEDLINE, PsycINFO, and registries of clinical trials...
June 28, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28655284/clozapine-response-rates-among-people-with-treatment-resistant-schizophrenia-data-from-a-systematic-review-and-meta-analysis
#11
Dan Siskind, Victor Siskind, Steve Kisely
Clozapine is the most effective antipsychotic for the 25% to 33% of people with schizophrenia who are treatment resistant, but not all people achieve response. Using data from a previously published clozapine systematic review and meta-analysis, we explored the proportion of people who achieved response and examined the absolute and percentage change in Positive and Negative Syndrome Scale (PANSS) scores. Overall, 40.1% (95% confidence interval [CI], 36.8%-43.4%) responded, with a mean reduction in PANSS of 22...
January 1, 2017: Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie
https://www.readbyqxmd.com/read/28638191/tai-chi-for-schizophrenia-a-systematic-review
#12
Wei Zheng, Qiang Li, Jingxia Lin, Yingqiang Xiang, Tong Guo, Qiong Chen, Dongbin Cai, Yutao Xiang
BACKGROUND: Tai Chi as a form of moderate aerobic exercise originating in China, could promote balance and healing of the mind-body. Furthermore, Tai Chi has been used as an adjunctive treatment for patients with schizophrenia. However, no meta-analysis or systematic review on adjunctive Tai Chi for patients with schizophrenia has yet been reported. AIM: A systematic review and meta-analysis was conducted to examine the efficacy of Tai Chi as an adjunctive treatment for schizophrenia using randomized controlled trial (RCT) data...
August 25, 2016: Shanghai Archives of Psychiatry
https://www.readbyqxmd.com/read/28613100/myocardial-infarction-risk-and-antipsychotics-use-revisited-a-meta-analysis-of-10-observational-studies
#13
Kai-Lin Huang, Ching-Ju Fang, Chien-Chi Hsu, Shu-I Wu, Jimmy Jm Juang, Robert Stewart
OBJECTIVE: Associations between antipsychotic agent (AP) use and myocardial infarction (MI) risk have been inconsistent and remain controversial. We therefore conducted a meta-analysis of observational studies to address this knowledge gap. METHOD: Detailed electronic database searches were performed to identify reports of observational studies that evaluated the association between AP use and the risk of MI. Pooled odds ratios (ORs) were calculated using random or fixed-effects models...
June 1, 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/28612979/research-and-practice-for-ultra-high-risk-for-psychosis-a-national-survey-of-early-intervention-in-psychosis-services-in-england
#14
Helen J Stain, Lauren Mawn, Stephanie Common, Marie Pilton, Andrew Thompson
BACKGROUND: Evidence from meta-analyses of randomized clinical trials show interventions for young people at ultra-high risk (UHR) of developing psychosis are effective both clinically and economically. While research evidence has begun to be integrated into clinical guidelines, there is a lack of research on the implementation of these guidelines. This paper examines service provision for UHR individuals in accordance with current clinical guidelines within the National Health Service (NHS) in England...
June 14, 2017: Early Intervention in Psychiatry
https://www.readbyqxmd.com/read/28578741/antipsychotic-combinations-in-schizophrenia
#15
C Gastaldon, D Papola, G Ostuzzi
In the treatment of resistant schizophrenia, a number of meta-analyses attempted to quantify the efficacy and tolerability of antipsychotic (AP) polypharmacy v. monotherapy with contradictory results. Recently, a systematic review and meta-analysis of randomised controlled trials investigated the efficacy and tolerability of AP combination v. monotherapy in schizophrenia. It included 31 studies: 21 double-blind (considered high-quality studies) and 10 open-label (considered low-quality studies). The meta-analysis showed that, overall, the combination of two APs was more effective than monotherapy in terms of symptom reduction (standardised mean difference (SMD) = -0...
June 5, 2017: Epidemiology and Psychiatric Sciences
https://www.readbyqxmd.com/read/28566947/immunological-aspects-of-the-treatment-of-depression-and-schizophrenia
#16
Norbert Müller
Schizophrenia and major depression (MD) have been associated with immune system dysfunction. One example of this is the altered level of cytokines-important inflammatory mediators-in blood, and a proinflammatory immune state has been described in some subgroups of patients. A knock to the immune system in early life might trigger a life-long increased immune reactivity, and infections and autoimmune disorders are now known to be risk factors for development of schizophrenia and MD. Pro- and anti-inflammatory cytokines mediate indoleamine 2,3-dioxygenase activity; this enzyme drives metabolism of tryptophan and kynurenin in the central nervous system and degrades serotonin...
March 2017: Dialogues in Clinical Neuroscience
https://www.readbyqxmd.com/read/28553116/comparative-efficacy-and-safety-of-antipsychotics-in-the-treatment-of-schizophrenia-a-network-meta-analysis-in-a-japanese-population
#17
Taro Kishi, Toshikazu Ikuta, Shinji Matsunaga, Yuki Matsuda, Kazuto Oya, Nakao Iwata
BACKGROUND: The relative efficacy and tolerability of antipsychotics for schizophrenia are considerably well studied. This study aimed to examine whether previous findings could be replicated in a genetically distinct and homogenous group (ie, Japanese patients with schizophrenia) and whether previous findings could be extended to a broader range of antipsychotics with previously unclear relative efficacy and tolerability. METHODS: Bayesian network meta-analysis was performed in which randomized trials comparing any of the following interventions were included: second-generation antipsychotics, haloperidol, or placebo...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28545597/prefrontal-cortical-thinning-links-to-negative-symptoms-in-schizophrenia-via-the-enigma-consortium
#18
E Walton, D P Hibar, T G M van Erp, S G Potkin, R Roiz-Santiañez, B Crespo-Facorro, P Suarez-Pinilla, N E M van Haren, S M C de Zwarte, R S Kahn, W Cahn, N T Doan, K N Jørgensen, T P Gurholt, I Agartz, O A Andreassen, L T Westlye, I Melle, A O Berg, L Morch-Johnsen, A Færden, L Flyckt, H Fatouros-Bergman, E G Jönsson, R Hashimoto, H Yamamori, M Fukunaga, N Jahanshad, P De Rossi, F Piras, N Banaj, G Spalletta, R E Gur, R C Gur, D H Wolf, T D Satterthwaite, L M Beard, I E Sommer, S Koops, O Gruber, A Richter, B Krämer, S Kelly, G Donohoe, C McDonald, D M Cannon, A Corvin, M Gill, A Di Giorgio, A Bertolino, S Lawrie, T Nickson, H C Whalley, E Neilson, V D Calhoun, P M Thompson, J A Turner, S Ehrlich
BACKGROUND: Our understanding of the complex relationship between schizophrenia symptomatology and etiological factors can be improved by studying brain-based correlates of schizophrenia. Research showed that impairments in value processing and executive functioning, which have been associated with prefrontal brain areas [particularly the medial orbitofrontal cortex (MOFC)], are linked to negative symptoms. Here we tested the hypothesis that MOFC thickness is associated with negative symptom severity...
May 26, 2017: Psychological Medicine
https://www.readbyqxmd.com/read/28541090/sixty-years-of-placebo-controlled-antipsychotic-drug-trials-in-acute-schizophrenia-systematic-review-bayesian-meta-analysis-and-meta-regression-of-efficacy-predictors
#19
Stefan Leucht, Claudia Leucht, Maximilian Huhn, Anna Chaimani, Dimitris Mavridis, Bartosz Helfer, Myrto Samara, Matteo Rabaioli, Susanne Bächer, Andrea Cipriani, John R Geddes, Georgia Salanti, John M Davis
OBJECTIVE: Antipsychotic drug efficacy may have decreased over recent decades. The authors present a meta-analysis of all placebo-controlled trials in patients with acute exacerbations of schizophrenia, and they investigate which trial characteristics have changed over the years and which are moderators of drug-placebo efficacy differences. METHOD: The search included multiple electronic databases. The outcomes were overall efficacy (primary outcome); responder and dropout rates; positive, negative, and depressive symptoms; quality of life; functioning; and major side effects...
May 25, 2017: American Journal of Psychiatry
https://www.readbyqxmd.com/read/28522434/one-year-symptom-trajectories-in-patients-with-stable-schizophrenia-maintained-on-antipsychotics-versus-placebo-meta-analysis
#20
REVIEW
Hiroyoshi Takeuchi, Navot Kantor, Marcos Sanches, Gagan Fervaha, Ofer Agid, Gary Remington
BackgroundAs definitions of relapse differ substantially between studies, in investigations involving data aggregation, total scores on clinical rating scales provide a more generalisable outcome.AimsTo compare total symptom trajectories for antipsychotic versus placebo treatment over a 1-year period of maintenance treatment in schizophrenia.MethodRandomised controlled trials with antipsychotic and placebo treatment arms in patients with stable schizophrenia that reported Positive and Negative Syndrome Scale and Brief Psychiatric Rating Scale total scores at more than one time point were included...
May 18, 2017: British Journal of Psychiatry: the Journal of Mental Science
keyword
keyword
109203
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"